Methylation profile of the <i>MLH1</i> promoter region and their relationship to colorectal carcinogenesis

抄録

<jats:title>Abstract</jats:title><jats:p>Methylation of the <jats:italic>MLH1</jats:italic> promoter region has been suggested to be a principal mechanism of gene inactivation in sporadic microsatellite instability (MSI)–positive colorectal carcinoma. Recently, we have shown a novel methylation profile of the <jats:italic>MLH1</jats:italic> promoter region (i.e., full, partial, and no methylation), among which full methylation was strongly associated with MSI. In this study, to confirm whether methylation requires the involvement of both alleles, we studied the <jats:italic>MLH1</jats:italic> promoter region concerning the methylation profile and allelic loss. Furthermore, we studied correlations of methylation profiles with genetic alternations such as loss of heterozygosity (LOH) of the <jats:italic>TP53</jats:italic> locus and <jats:italic>KRAS</jats:italic> mutation. Eighty‐eight tumors were classified as full (<jats:italic>n</jats:italic> = 14), partial (<jats:italic>n</jats:italic> = 26), and no methylation (<jats:italic>n</jats:italic> = 48). Full methylation was observed in 78% (14/18) of high‐frequency MSI, in which all CpG sites in the promoter region were methylated. Full methylation differed significantly from partial methylation regarding absence of <jats:italic>TP53</jats:italic> LOH (0/12) and <jats:italic>KRAS</jats:italic> mutation (0/14). In cases with full methylation, we could show biallelic methylation by use of a single‐base nucleotide polymorphism in the promoter. However, this did not accompany LOH of the <jats:italic>MLH1</jats:italic> locus. In contrast, there were no significant differences in molecular features between partial and no methylation, except for low frequencies of LOH of the <jats:italic>MLH1</jats:italic> locus (<jats:italic>P</jats:italic> = 0.02). In conclusion, biallelic extensive methylation of the <jats:italic>MLH1</jats:italic> promoter region plays a significant role in gene inactivation and is independent of <jats:italic>KRAS</jats:italic> mutation and <jats:italic>TP53</jats:italic> LOH. © 2002 Wiley‐Liss, Inc.</jats:p>

収録刊行物

被引用文献 (4)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ